10 Nov, 2026

Breast cancer pill from AstraZeneca misses mark in pivotal study

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — AstraZeneca said Friday that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors, a result that could limit the use of the […]

2 mins read

Hims & Hers Won’t Sell Compound Version of Novo’s Obesity Pill

Hims & Hers announced Saturday that it would stop selling what it claims is a cheaper, compounded version of Novo Nordisk’s obesity pill on its telehealth platform, after health officials called for an investigation into the company for potential violations of federal law. Hims launched the compounded drug earlier this week at $49 per month. […]

1 min read